ATRAG formulations for lung disease

2023-08-14T10:27:20

Image

Carl-Johan Dalsgaard, CEO of Vicore Pharma speaks to EPR about clinical trials of C21, an angiotensin II type 2 receptor agonist developed to treat rare lung diseases – and the first ever ATRAG to reach clinical-stage development.

Already a member? Sign-in

Unlock

Driving innovation in pharma manufacturing

European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.

Become a member to continue reading

By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:

  • Unlimited access to industry intelligence that can make a difference to your business
  • A weekly newsletter keeping the most vital information at the front of your thinking
  • Exclusive invitations to powerful webinars and events featuring high profile experts
  • Access to deep-dive reports and analysis that reveal exciting new opportunities for business growth and transformation

Become a member